Yield10 Bioscience (NASDAQ:YTEN – Get Free Report) and 10X Capital Venture Acquisition Corp. II (NASDAQ:VCXA – Get Free Report) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.
Volatility and Risk
Yield10 Bioscience has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, 10X Capital Venture Acquisition Corp. II has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.
Valuation & Earnings
This table compares Yield10 Bioscience and 10X Capital Venture Acquisition Corp. II’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Yield10 Bioscience | $450,000.00 | 4.04 | -$13.57 million | ($2.78) | -0.11 |
| 10X Capital Venture Acquisition Corp. II | N/A | N/A | -$8.68 million | N/A | N/A |
Analyst Ratings
This is a summary of recent ratings for Yield10 Bioscience and 10X Capital Venture Acquisition Corp. II, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Yield10 Bioscience | 0 | 0 | 2 | 0 | 3.00 |
| 10X Capital Venture Acquisition Corp. II | 0 | 0 | 0 | 0 | N/A |
Yield10 Bioscience presently has a consensus price target of $3.50, suggesting a potential upside of 1,076.47%. Given Yield10 Bioscience’s higher probable upside, analysts plainly believe Yield10 Bioscience is more favorable than 10X Capital Venture Acquisition Corp. II.
Insider & Institutional Ownership
10.8% of Yield10 Bioscience shares are held by institutional investors. Comparatively, 20.5% of 10X Capital Venture Acquisition Corp. II shares are held by institutional investors. 9.4% of Yield10 Bioscience shares are held by company insiders. Comparatively, 48.4% of 10X Capital Venture Acquisition Corp. II shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Yield10 Bioscience and 10X Capital Venture Acquisition Corp. II’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Yield10 Bioscience | -3,882.82% | -427.12% | -186.58% |
| 10X Capital Venture Acquisition Corp. II | N/A | N/A | -5.44% |
Summary
10X Capital Venture Acquisition Corp. II beats Yield10 Bioscience on 6 of the 10 factors compared between the two stocks.
About Yield10 Bioscience
Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.
About 10X Capital Venture Acquisition Corp. II
10X Capital Venture Acquisition Corp. II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on identifying technology and tech-enabled businesses in the consumer internet, ecommerce, software, healthcare, transportation/mobility, and financial services industries, as well as other industries that are being disrupted by advances in technology and on technology paradigms, including artificial intelligence automation, data science, ecommerce, and software-as-a-service. The company was incorporated in 2021 and is based in New York, New York.
Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
